Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SEER 
Seer Inc (SEER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SEER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.2% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.93M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 3 | Beta 1.58 | 52 Weeks Range 1.62 - 2.62 | Updated Date 09/16/2025 |
52 Weeks Range 1.62 - 2.62 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -506.79% |
Management Effectiveness
Return on Assets (TTM) -15.27% | Return on Equity (TTM) -25.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -69499356 | Price to Sales(TTM) 7.06 |
Enterprise Value -69499356 | Price to Sales(TTM) 7.06 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 52294400 | Shares Floating 40279247 |
Shares Outstanding 52294400 | Shares Floating 40279247 | ||
Percent Insiders 3.39 | Percent Institutions 65.42 |
Upturn AI SWOT
Seer Inc
Company Overview
History and Background
Seer, Inc. was founded in 2017. It is focused on proteomics, and the company went public via SPAC in 2020. Seer aims to transform proteomics by providing products and services that enable unbiased, deep, and rapid proteomic profiling.
Core Business Areas
- Proteogenomic Solutions: Seer provides a platform for proteogenomic analysis, enabling researchers to study proteins and genes simultaneously.
- Reagent and Kit Sales: Seer sells reagents, kits, and consumables necessary for using its proteomic platform.
- Services: Seer offers proteomic analysis services to researchers and biopharmaceutical companies.
Leadership and Structure
Omead Ostadan is the CEO of Seer, Inc. The company has a typical corporate structure with departments focused on R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Proteograph Product Suite: Seer's flagship product is the Proteograph Product Suite, which includes the Proteograph XT Assay Kit, instruments, and software. This platform enables high-throughput proteomic analysis. Market share data is not publicly available. Competitors include SomaLogic, Olink Proteomics, and Thermo Fisher Scientific.
- Seer Proteograph Analysis Software: The software used in the platform to help process results from the Proteograph XT Assay Kit. Market share data is not publicly available. Competitors include SomaLogic, Olink Proteomics, and Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The proteomics market is growing rapidly, driven by increasing demand for personalized medicine and drug discovery. It is a rapidly growing segment within genomics.
Positioning
Seer aims to be a leader in the proteomics market by providing innovative tools for deep proteomic profiling. Seer believes its solution offers improvements over competitors by being able to sample a wider area of the proteome.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars. Seer is positioned to capture a significant share by offering advanced proteomic solutions.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong IP portfolio
- Scalable platform
Weaknesses
- Limited market adoption compared to established players
- High cost of initial investment for customers
- Reliance on third-party suppliers
Opportunities
- Expanding applications in drug discovery and diagnostics
- Partnerships with pharmaceutical companies
- Increasing demand for personalized medicine
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- DNA
Competitive Landscape
Seer competes with larger, more established players in the genomics and proteomics markets. Seer's advantage lies in its innovative technology, but it needs to demonstrate broader market adoption to compete effectively.
Major Acquisitions
Proteome Software, Inc
- Year: 2023
- Acquisition Price (USD millions): 7.5
- Strategic Rationale: The acquisition of Proteome Software strengthens Seer's bioinformatics capabilities and enhances its proteomic analysis platform.
Growth Trajectory and Initiatives
Historical Growth: Revenue has grown significantly since the company's inception, but growth rates are variable.
Future Projections: Analysts expect continued revenue growth as the proteomics market expands and Seer gains further market share. However, profitability is not expected in the near term.
Recent Initiatives: Seer has been focused on expanding its product portfolio and building partnerships with key opinion leaders and pharmaceutical companies.
Summary
Seer is an innovative proteomics company with a promising technology platform. While the company has shown revenue growth and has a strong cash position, it still operates at a loss and faces competition from larger, more established players. Its future success depends on continued revenue growth, market adoption, and managing expenses effectively. Further acquisitions could help the company expand its offerings and market reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Seer, Inc. SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Please conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seer Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-12-04 | Founder, CEO, & Chair of the Board of Directors Dr. Omid C. Farokhzad M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://seer.bio |
Full time employees 134 | Website https://seer.bio | ||
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.